Qiwen Huang
Overview
Explore the profile of Qiwen Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zha W, Ou Q, Zhang Y, Huang Q, Li J, Wen M
World J Emerg Med
. 2024 Nov;
15(6):494-498.
PMID: 39600817
No abstract available.
2.
Li P, Huang Q, Xie Y, Zhu Z, Zhan S, Meng J, et al.
Arch Microbiol
. 2024 Nov;
206(12):470.
PMID: 39560788
The increasing drug resistance of Mycobacterium tuberculosis (Mtb), coupled with the limited availability of effective anti-tuberculosis medications, poses significant challenges for the management and treatment of tuberculosis (TB). Globally, non-tuberculous...
3.
Huang E, Huang Q, Kenkare P, Mudiganti S, Martinez M, Liang S
Gastrointest Endosc
. 2024 Oct;
PMID: 39481577
Background And Aims: Adenoma detection rate (ADR) is a key quality metric in colonoscopy, reflecting the ability to detect adenomas. However, concerns remain regarding the robustness of ADR as a...
4.
Brar S, Huang Q, Yan X, Dudum R, Jose P, Sarraju A, et al.
J Gen Intern Med
. 2024 Oct;
PMID: 39455482
Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and clinical guidelines recommend incorporating Lp(a) testing in routine care. Objective: Examine real-world, contemporary clinical testing patterns...
5.
Huang Q, Hu J, Mei D, Li G, Rong J
Prep Biochem Biotechnol
. 2024 Jul;
55(2):160-170.
PMID: 39028537
Recombinant human acidic fibroblast growth factor (rh-aFGF) is a widely used biological product, but it is unstable and its biological activity is easy to decrease. In order to maintain the...
6.
Dudum R, Huang Q, Yan X, Fonseca M, Jose P, Sarraju A, et al.
JACC Adv
. 2024 Jun;
3(6):100940.
PMID: 38938854
Background: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Objectives: The authors assessed differences in Lp(a) testing and levels by disaggregated race, ethnicity, and ASCVD risk....
7.
Dillon E, Deng S, Li M, Huang Q, de Vera E, Pesa J, et al.
Psychiatr Res Clin Pract
. 2024 Jun;
6(2):51-60.
PMID: 38854873
Objective: Sutter Health launched system-wide general population standardized suicide screening with the Columbia-Suicide Severity Rating Scale (C-SSRS) screen (triage) version in 23 hospitals in 2019, replacing a one-question "danger to...
8.
Sarraju A, Yan X, Huang Q, Dudum R, Palaniappan L, Rodriguez F
Am J Prev Cardiol
. 2024 Mar;
17:100647.
PMID: 38525197
Objective: There remain disparities by race and ethnicity in atherosclerotic cardiovascular disease (ASCVD). Statins reduce low-density lipoprotein cholesterol (LDL-c) and improve ASCVD outcomes. ASCVD treatment patterns across disaggregated race and...
9.
Azar K, Sudat S, Huang Q, Pressman A, Szwerinski N, Nasrallah C, et al.
Obes Sci Pract
. 2023 Dec;
9(6):641-652.
PMID: 38090689
Objective: Evaluations of lifestyle modification interventions (LMIs), modeled after the Diabetes Prevention Program, have repeatedly shown a dose-response relationship between session attendance and weight loss. Despite this, not all participants...
10.
Sudat S, Huang Q, Szwerinski N, Romanelli R, Azar K
Am J Prev Med
. 2023 Oct;
66(4):619-626.
PMID: 37907133
Introduction: This study evaluates the real-world impact of a lifestyle change program (LCP) on healthcare utilization in a large health system. Methods: Using electronic health record data from a large...